AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters

被引:61
作者
Sanftner, LM
Sommer, JM
Suzuki, BM
Smith, PH
Vijay, S
Vargas, JA
Forsayeth, JR
Cunningham, J
Bankiewicz, KS
Kao, HW
Bernal, J
Pierce, GF
Johnson, KW
机构
[1] Avigen Inc, Alameda, CA 94502 USA
[2] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94103 USA
[3] Charles River Labs Inc, Discovery & Dev Serv, Sierra Div, Sparks, NV 89431 USA
关键词
adeno-associated virus; aromatic L-amino acid decarboxylase; Parkinson's disease; brain; infusion device; putamen; convection-enhanced delivery; AAV-hAADC-2;
D O I
10.1016/j.expneurol.2005.03.007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this study, a modified infusion procedure and a novel infusion device designed for use in humans (Clinical Device B) were evaluated for delivery of recombinant adeno-associated virus (AAV2) to brain. The device is composed of 1.2 in of fused silica inserted through a 24.6 cm surgical steel cannula designed to fit a standard Leksell (R) clinical stereotaxic frame and micro-infusion syringe pump. AAV2 encoding the human aromatic L-amino acid decarboxylase gene (AAV-hAADC-2) was infused into the putamen of 4 normal rhesus monkeys as a supportive study for a clinical trial in Parkinson's disease (PD) patients. Two infusion protocols were tested: a ramped procedure (slow stepwise increases in rate from 0.2 mu L/min to 1 mu L/min), thought to be essential for convection-enhanced delivery (CED), and a non-ramped infusion at a constant rate of I mu L/min. The primary endpoints were safety evaluation of the infusion procedures and assessment of transgene expression at 5.5 weeks post-infusion. Clinical observations after vector infusions revealed no behavioral abnormalities during the study period. No differences in gross pathology with either the ramped or non-ramped infusion procedure were observed. Histopathology of the putamen was comparable with both procedures, and revealed only minimal localized inflammatory tissue reaction along the needle track in response to cannula placement and vector infusion. AADC immunohistochemistry demonstrated that vector was distributed throughout the putamen, with no significant difference in volume of immunostaining with either infusion procedure. Serum antibody levels against AAV2 vector exhibited a minor increase after infusion. These results validate the clinical utility of this new infusion device and non-ramped infusion conditions for intraputamenal gene therapy, and have the potential to impact a number of human diseases in which delivery of therapeutics to brain is indicated. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:476 / 483
页数:8
相关论文
共 15 条
[1]   Convection-enhanced delivery of AAV vector in parkinsonian monkeys;: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach [J].
Bankiewicz, KS ;
Eberling, JL ;
Kohutnicka, M ;
Jagust, W ;
Pivirotto, P ;
Bringas, J ;
Cunningham, J ;
Budinger, TF ;
Harvey-White, J .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :2-14
[2]  
BLACKLOW NR, 1968, J NATL CANCER I, V40, P319
[3]   CONVECTION-ENHANCED DELIVERY OF MACROMOLECULES IN THE BRAIN [J].
BOBO, RH ;
LASKE, DW ;
AKBASAK, A ;
MORRISON, PF ;
DEDRICK, RL ;
OLDFIELD, EH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2076-2080
[4]   Novel tools for production and purification of recombinant adenoassociated virus vectors [J].
Grimm, D ;
Kern, A ;
Rittner, K ;
Kleinschmidt, JA .
HUMAN GENE THERAPY, 1998, 9 (18) :2745-2760
[5]  
Hornykiewicz O, 1975, Natl Inst Drug Abuse Res Monogr Ser, P13
[6]   Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor [J].
Kroll, RA ;
Pagel, MA ;
Muldoon, LL ;
RomanGoldstein, S ;
Neuwelt, EA .
NEUROSURGERY, 1996, 38 (04) :746-752
[7]   CONVECTION-ENHANCED DISTRIBUTION OF LARGE MOLECULES IN GRAY-MATTER DURING INTERSTITIAL DRUG INFUSION [J].
LIEBERMAN, DM ;
LASKE, DW ;
MORRISON, PF ;
BANKIEWICZ, KS ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1995, 82 (06) :1021-1029
[8]   Adeno-associated virus vectors can be efficiently produced without helper virus [J].
Matsushita, T ;
Elliger, S ;
Elliger, C ;
Podsakoff, G ;
Villarreal, L ;
Kurtzman, GJ ;
Iwaki, Y ;
Colosi, P .
GENE THERAPY, 1998, 5 (07) :938-945
[9]   Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats [J].
Sánchez-Pernaute, R ;
Harvey-White, J ;
Cunningham, J ;
Bankiewicz, KS .
MOLECULAR THERAPY, 2001, 4 (04) :324-330
[10]   Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV [J].
Sanftner, LM ;
Suzuki, BM ;
Doroudchi, MM ;
Feng, L ;
McClelland, A ;
Forsayeth, JR ;
Cunningham, J .
MOLECULAR THERAPY, 2004, 9 (03) :403-409